Targets

Target Filters...

This is where graphics are reside..

Name	Gene	Development Level	Target Family	Log Novelty	Pubmed Score	Antibody Count
DNA polymerase delta catalytic subunit	POLD1	Tclin	Enzyme	-2.02098	96.6	198
V-type proton ATPase 116 kDa subunit a isoform 2	ATP6V0A2	Tbio	Enzyme	-2.43448	279.3	62
Lysyl oxidase homolog 2	LOXL2	Tbio	Enzyme	-2.17984	142.0	237
Metal-response element-binding transcription factor 2	MTF2	Tbio	Epigenetic	-1.74028	52.0	101
Mitochondrial coenzyme A transporter SLC25A42	SLC25A42	Tbio	Transporter	-0.38872	3.06	24
Equilibrative nucleoside transporter 1	SLC29A1	Tclin	Transporter	-2.59024	397.3	363
MARVEL domain-containing protein 1	MARVELD1	Tbio	Non-IDG	-1.56013	36.2	57
E3 ubiquitin-protein ligase RNF115	RNF115	Tbio	Enzyme	-1.29757	20.6	76
Cullin-associated NEDD8-dissociated protein 1	CAND1	Tbio	Non-IDG	-1.85520	69.1	156
SH3 domain-binding glutamic acid-rich-like protein 2	SH3BGRL2	Tbio	Non-IDG	0.08	0.71	6

	Tbio	2,697 \| 10,625
	Tdark	1,017 \| 7,003
	Tchem	482 \| 1,890
	Tclin	173 \| 602

	Eligible Ion Channel Proteins	35 \| 117
	Eligible Kinase Proteins	33 \| 134
	Eligible non-olfactory GPCR Proteins	19 \| 145

	preweaning lethality, complete...	156 \| 633
	preweaning lethality, incomple...	89 \| 260
	abnormal behavior	84 \| 226
	decreased lean body mass	66 \| 195
	decreased total body fat amoun...	64 \| 186
	decreased bone mineral content	60 \| 157
	decreased body weight	53 \| 174
	embryonic lethality prior to t...	52 \| 187
	decreased grip strength	48 \| 123
	hyperactivity	44 \| 108
	decreased body length	43 \| 108
	abnormal bone structure	42 \| 131
	decreased bone mineral density	42 \| 126
	increased lean body mass	42 \| 107
	increased or absent threshold ...	41 \| 128
	increased circulating alkaline...	38 \| 119
	decreased circulating choleste...	37 \| 85
	hypoactivity	35 \| 89
	decreased circulating HDL chol...	34 \| 77
	short tibia	34 \| 82
	abnormal embryo size	33 \| 112
	abnormal retina morphology	33 \| 100
	embryonic lethality prior to o...	31 \| 148
	increased bone mineral content	30 \| 92
	decreased circulating glucose ...	29 \| 121
	decreased circulating triglyce...	29 \| 83
	increased mean corpuscular vol...	29 \| 91
	decreased circulating serum al...	28 \| 79
	abnormal lens morphology	27 \| 73
	increased mean corpuscular hem...	25 \| 93
	abnormal sleep behavior	24 \| 63
	decreased prepulse inhibition	24 \| 52
	enlarged heart	24 \| 111
	increased fasted circulating g...	23 \| 68
	increased grip strength	23 \| 83
	abnormal coat/hair pigmentatio...	22 \| 54
	decreased fasted circulating g...	22 \| 49
	decreased lumbar vertebrae num...	22 \| 62
	abnormal gait	21 \| 51
	decreased mean corpuscular vol...	21 \| 50
	increased sacral vertebrae num...	21 \| 62
	decreased circulating alanine ...	20 \| 53
	decreased hemoglobin content	20 \| 53
	male infertility	20 \| 62
	decreased circulating LDL chol...	19 \| 37
	decreased circulating insulin ...	19 \| 75
	decreased leukocyte cell numbe...	19 \| 54
	increased blood urea nitrogen ...	19 \| 44
	increased circulating HDL chol...	19 \| 63
	decreased caudal vertebrae num...	18 \| 49
	decreased startle reflex	17 \| 48
	impaired glucose tolerance	17 \| 52
	increased circulating chloride...	17 \| 43
	increased startle reflex	17 \| 38
	prenatal lethality prior to he...	17 \| 64
	abnormal bone mineralization	16 \| 55
	decreased erythrocyte cell num...	16 \| 43
	decreased rib number	16 \| 59
	increased circulating calcium ...	16 \| 32
	increased circulating choleste...	16 \| 53
	increased total body fat amoun...	16 \| 57
	decreased circulating total pr...	15 \| 41
	decreased heart weight	15 \| 44
	improved glucose tolerance	15 \| 56
	increased circulating sodium l...	15 \| 71
	thrombocytopenia	15 \| 46
	abnormal retinal pigmentation	14 \| 61
	tremors	14 \| 34
	abnormal behavioral response t...	13 \| 52
	decreased circulating creatini...	13 \| 31
	increased bone mineral density	13 \| 52
	increased hemoglobin content	13 \| 45
	limb grasping	13 \| 35
	abnormal heart morphology	12 \| 51
	cardiovascular system phenotyp...	12 \| 35
	decreased blood urea nitrogen ...	12 \| 31
	decreased circulating alkaline...	12 \| 41
	increased body weight	12 \| 42
	increased rib number	12 \| 41
	abnormal eye morphology	11 \| 38
	abnormal neural tube closure	11 \| 37
	abnormal rib morphology	11 \| 28
	decreased circulating free fat...	11 \| 39
	decreased circulating fructosa...	11 \| 31
	decreased eosinophil cell numb...	11 \| 41
	decreased threshold for audito...	11 \| 32
	increased circulating iron lev...	11 \| 25
	increased circulating phosphat...	11 \| 24
	increased exploration in new e...	11 \| 56
	increased heart weight	11 \| 37
	increased hematocrit	11 \| 36
	abnormal kidney morphology	10 \| 30
	cataract	10 \| 26
	decreased circulating aspartat...	10 \| 27
	decreased mean corpuscular hem...	10 \| 34
	female infertility	10 \| 34
	increased leukocyte cell numbe...	10 \| 37
	abnormal spleen morphology	9 \| 36
	decreased vertical activity	9 \| 22
	increased circulating potassiu...	9 \| 31

	atypical teratoid / rhabdoid tumor	4,369 \| 4,369
	ovarian cancer	8,492 \| 8,492
	osteosarcoma	7,933 \| 7,933
	psoriasis	6,685 \| 6,685
	medulloblastoma, large-cell	6,234 \| 6,234
	glioblastoma	5,572 \| 5,572
	lung cancer	4,473 \| 4,473
	intraductal papillary-mucinous neoplasm (IPMN)	3,289 \| 3,289
	malignant mesothelioma	3,163 \| 3,163
	Breast cancer	3,099 \| 3,099
	pilocytic astrocytoma	3,086 \| 3,086
	primitive neuroectodermal tumor	3,031 \| 3,031
	intraductal papillary-mucinous carcinoma (IPMC)	2,988 \| 2,988
	intraductal papillary-mucinous adenoma (IPMA)	2,956 \| 2,956
	invasive ductal carcinoma	2,950 \| 2,950
	oligodendroglioma	2,849 \| 2,849
	lung carcinoma	2,844 \| 2,844
	non-small cell lung cancer	2,798 \| 2,798
	lung adenocarcinoma	2,714 \| 2,714
	pediatric high grade glioma	2,712 \| 2,712
	ependymoma	2,514 \| 2,514
	Cancer	2,346 \| 2,346
	pancreatic cancer	2,300 \| 2,300
	interstitial cystitis	2,299 \| 2,299
	subependymal giant cell astrocytoma	2,287 \| 2,287
	group 3 medulloblastoma	2,254 \| 2,254
	astrocytic glioma	2,241 \| 2,241
	adult high grade glioma	2,148 \| 2,148
	Carcinoma	2,147 \| 2,147
	ulcerative colitis	2,087 \| 2,087
	pituitary cancer	1,972 \| 1,972
	Pick disease	1,893 \| 1,893
	group 4 medulloblastoma	1,875 \| 1,875
	pancreatic ductal adenocarcinoma liver metastasis	1,795 \| 1,795
	ductal carcinoma in situ	1,745 \| 1,745
	cystic fibrosis	1,670 \| 1,670
	diabetes mellitus	1,663 \| 1,663
	breast carcinoma	1,614 \| 1,614
	tuberculosis	1,563 \| 1,563
	posterior fossa group B ependymoma	1,530 \| 1,530
	medulloblastoma	1,524 \| 1,524
	posterior fossa group A ependymoma	1,511 \| 1,511
	astrocytoma	1,493 \| 1,493
	sonic hedgehog group medulloblastoma	1,482 \| 1,482
	colon cancer	1,475 \| 1,475
	adrenocortical carcinoma	1,427 \| 1,427
	Multiple myeloma	1,328 \| 1,328
	primary pancreatic ductal adenocarcinoma	1,271 \| 1,271
	juvenile dermatomyositis	1,189 \| 1,189
	Rheumatoid Arthritis	1,171 \| 1,171
	acute quadriplegic myopathy	1,157 \| 1,157
	atypical teratoid/rhabdoid tumor	1,095 \| 1,095
	spina bifida	1,064 \| 1,064
	cutaneous lupus erythematosus	1,056 \| 1,056
	nasopharyngeal carcinoma	1,056 \| 1,056
	dermatomyositis	967 \| 967
	Atopic dermatitis	944 \| 944
	active Crohn's disease	918 \| 918
	non primary Sjogren syndrome sicca	840 \| 840
	gastric carcinoma	832 \| 832
	primary Sjogren syndrome	789 \| 789
	acute myeloid leukemia	785 \| 785
	Waldenstrons macroglobulinemia	765 \| 765
	esophageal adenocarcinoma	737 \| 737
	tuberculosis and treatment for 6 months	686 \| 686
	progressive supranuclear palsy	674 \| 674
	aldosterone-producing adenoma	664 \| 664
	Alzheimer's disease	644 \| 644
	Obesity	616 \| 616
	Duchenne muscular dystrophy	602 \| 602
	Intellectual disability	573 \| 573
	pancreatic carcinoma	567 \| 567
	fibroadenoma	557 \| 557
	hepatocellular carcinoma	550 \| 550
	Down syndrome	548 \| 548
	Endometriosis	535 \| 535
	chronic rhinosinusitis	512 \| 512
	Schizophrenia	503 \| 503
	autosomal dominant Emery-Dreifuss muscular dystrophy	499 \| 499
	Multiple Sclerosis	498 \| 498
	mucosa-associated lymphoid tissue lymphoma	480 \| 480
	active ulcerative colitis	477 \| 477
	Prostatic Neoplasms	471 \| 471
	IGA Glomerulonephritis	454 \| 454
	gastric cancer	436 \| 436
	Amyotrophic Lateral Sclerosis	432 \| 432
	non-small cell lung carcinoma	413 \| 413
	Mammary Neoplasms	410 \| 410
	inflammatory breast cancer	404 \| 404
	Kidney disease	397 \| 397
	Neurodegenerative disease	383 \| 383
	sarcoidosis	368 \| 368
	Parkinson's disease	364 \| 364
	Asthma	349 \| 349
	glioblastoma multiforme	347 \| 347
	Epilepsy	346 \| 346
	Polycystic Ovary Syndrome	335 \| 335
	nephrosclerosis	329 \| 329
	tuberculosis and treatment for 3 months	327 \| 327
	Autistic Disorder	320 \| 320

	Nervous System	4,333 \| 18,561
	Female tissues	4,331 \| 18,647
	Digestive Tract	4,329 \| 18,473
	Liver and Pancreas	4,321 \| 18,136
	Endocrine System	4,317 \| 18,512
	Urinary Tract	4,317 \| 18,444
	Cardiovascular System	4,312 \| 17,958
	Male tissues	4,303 \| 17,969
	Blood and immune system	4,302 \| 17,995
	Skin and soft tissues	4,293 \| 18,115
	Respiratory system	4,278 \| 17,484

Development Level

Collection

IMPC Term

Disease

Tissue

Target Family

Drug Target Ontology

Target Development Level

Target Family

PANTHER Protein Ontology

Ligand

GTEx Tissue

HPA RNA Tissue

HPA Protein Tissue

HPM Tissue

JAX/MGI Phenotype

OMIM Phenotype

GWAS Trait

GO Component

UniProt Keywords

Grant Funding IC

Grant Activity

Data Source

	Non-IDG	2,546 \| 11,969
	Enzyme	925 \| 4,146
	Transcription Factor	306 \| 1,400
	Kinase	190 \| 634
	Transporter	121 \| 473
	Ion Channel	104 \| 341
	GPCR	79 \| 408
	Epigenetic	73 \| 242
	Nuclear Receptor	12 \| 48
	TF/Epigenetic	8 \| 38
	oGPCR	5 \| 421